Research of promotion and Support Headquarters
Profile Information
- Affiliation
- Professor and Chairperson, School of Medicine, Department of Gynecology, Fujita Health University
- Degree
- MD. Ph.D(Keio University)
- J-GLOBAL ID
- 200901003765483759
- researchmap Member ID
- 5000065794
Research Areas
1Major Research History
16-
Feb, 2023 - Present
Education
2-
Apr, 1991 - Mar, 1995
-
Apr, 1981 - Mar, 1987
Major Committee Memberships
25-
Jun, 2023 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
-
Jan, 2022 - Present
-
Jul, 2021 - Present
-
Apr, 2021 - Present
-
Apr, 2021 - Present
-
Jun, 2015 - Present
-
Jul, 2014 - Present
-
Sep, 2013 - Present
-
Aug, 2021 - Jul, 2023
-
Jul, 2020 - Jun, 2023
-
Jun, 2019 - Jun, 2021
Papers
109-
Cancer Science, 115(11) 3672-3681, Nov, 2024 Peer-reviewedLast authorCorresponding authorAbstract Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers for triage. Here, we evaluated whether metabolomic analysis of cervical mucus metabolism could be used to identify biomarkers of cervical intraepithelial neoplasia (CIN) and cervical cancer. The case–control group consisted of 181 CIN, 69 squamous cell carcinoma (SCC) patients, and 48 healthy controls in the primary cohort. We undertook metabolomic analyses using ultra‐HPLC–tandem mass spectrometry. Univariate and multivariate analyses were carried out to profile metabolite characteristics, and receiver operating characteristic (ROC) analysis identified biomarker candidates. Five metabolites conferred the highest discriminatory power for SCC: oxidized glutathione (GSSG) (area under the ROC curve, 0.924; 95% confidence interval, 0.877–0.971), malic acid (0.914, 0.859–0.968), kynurenine (0.884, 0.823–0.945), GSSG/glutathione (GSH) (0.936, 0.892–0.979), and kynurenine/tryptophan (0.909, 0.856–0.961). Malic acid was the best marker for detection of CIN2 or worse (0.858, 0.793–0.922) and was a clinically useful metabolite. We confirmed the reproducibility of the results by validation cohort. Additionally, metabolomic analyses revealed eight pathways strongly associated with cervical neoplasia. Of these, only the tricarboxylic acid cycle was strongly associated with all CINs and cancer, indicating active energy production. Aberrant arginine metabolism by decreasing arginine and increasing citrulline might reduce tumor immunity. Changes in cysteine‐methionine and GSH pathways might drive the initiation and progression of cervical cancer. These results suggest that metabolic analysis can identify ancillary biomarkers and could improve our understanding of the pathophysiological mechanisms underlying cervical neoplasia.
-
In vivo (Athens, Greece), 38(5) 2374-2382, Sep, 2024 Peer-reviewedBACKGROUND/AIM: The frequency rate of injection site reactions (ISR) due to fosaprepitant meglumine (Fos APR) has been shown to vary depending on the types of combined anticancer drug. This study aimed to elucidate the impact of Fos APR on ISR in patients receiving paclitaxel and carboplatin, with and without bevacizumab therapy (TC±Bev). PATIENTS AND METHODS: This study focused on patients with gynecologic cancer (n=93) who received TC±Bev administration at Fujita Health University Hospital from March 2016 to February 2020, and monitored up to six cycles. The patients were randomly assigned to the Fos APR group (n=47) and the Aprepitant (APR) group (n=46). Using Visual Infusion Phlebitis (VIP) scores, ISR was evaluated by comparing the VIP scores of all cycles using a linear mixed model. The risk factors that contribute to the occurrence of vascular pain throughout all cycles were also examined. RESULTS: The VIP scores of all cycles showed a near significant intergroup difference (p=0.071). Factors that affected the development of vascular pain included Fos APR and age (p=0.027 and 0.049, respectively). Regarding age, patients aged <65 years had a higher risk. Four patients underwent a switch from the originally assigned neurokinin-1 receptor antagonist; in all of these cases, Fos APR was changed to APR for vascular pain. CONCLUSION: Fos APR may increase the risk for ISR associated with TC±Bev therapy for gynecological cancer.
-
Scientific Reports, 14(1) 20000, Aug 28, 2024 Peer-reviewed
-
Cancer Science, 115(8) 2795-2807, May 15, 2024 Peer-reviewedLead authorCorresponding authorAbstract Currently, human papillomavirus tests and cytology are used to screen for cervical cancer. However, more accurate ancillary screening tests are needed. MicroRNAs (miRNAs) and cytokines are promising biomarkers that are aberrantly expressed in cervical cancer. Therefore, the potential of developing new screening markers based on the levels of miRNAs and cytokines in serum and local mucus samples from the same patients with cervical neoplasia was investigated. miRNA screening was performed by microarray and measurement using real‐time reverse‐transcriptase PCR. Cytokine were measured using multiplex bead assay, and changes in expressions were analyzed based on disease severity. As lesions progressed, miR‐20b‐5p, −155‐5p, −144‐3p, −451a, and −126‐3p expression levels were increased in mucus, and miR‐16‐5p, −223‐3p, and ‐451a expression levels were decreased in serum. Regarding cytokines, IL‐6, IL‐8, monocyte chemoattractant protein‐1, Eotaxin, interferon‐γ, and RANTES were increased, whereas granulocyte–colony‐stimulating factor (G‐CSF) was significantly decreased in mucus. miRNAs and cytokines in serum did not have high diagnostic accuracy. However, a combination of miR‐20b‐5p, ‐451a, ‐126‐3p, Eotaxin, as well as G‐CSF in mucus samples, had high diagnostic accuracy with an area under the receiver operating characteristic curve of 0.989 (0.979–0.999). Our results suggest that using mucus for this ancillary test is more beneficial than serum.
-
Journal of Obstetrics and Gynaecology Research, 50(7) 1073-1094, Apr 16, 2024 Peer-reviewedLast authorAbstract Twelve years after the first edition of The Guideline for Gynecological Practice, which was jointly edited by The Japan Society of Obstetrics and Gynecology and The Japan Association of Obstetricians and Gynecologists, the 5th Revised Edition was published in 2023. The 2023 Guidelines includes 5 additional clinical questions (CQs), which brings the total to 103 CQ (12 on infectious disease, 30 on oncology and benign tumors, 29 on endocrinology and infertility and 32 on healthcare for women). Currently, a consensus has been reached on the Guidelines, and therefore, the objective of this report is to present the general policies regarding diagnostic and treatment methods used in standard gynecological outpatient care that are considered appropriate. At the end of each answer, the corresponding Recommendation Level (A, B, C) is indicated.
Misc.
211-
日本産科婦人科学会雑誌, 76(12) 1795-1798, Dec 1, 2024 Lead authorCorresponding author
-
産婦人科の実際, 72(12) 1194-1201, Nov 30, 2023 InvitedLead authorCorresponding author
-
JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY, 39(1) 1-13, Sep 16, 2023 Lead authorCorresponding author
Books and Other Publications
51-
Springer Nature Singapore, Mar 22, 2024 (ISBN: 9789819993956)
Presentations
799-
The 36th International Papillomavirus Conference (IPVC 2024), Nov, 2024, International Papillomavirus Society (IPVS)
Professional Memberships
26Works
1Research Projects
13-
科学研究費助成事業 基盤研究(C), 日本学術振興会, Apr, 2023 - Mar, 2026
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
厚生労働科学研究費補助金, 厚生労働省, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2020 - Mar, 2023
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2017 - Mar, 2020
Industrial Property Rights
4Social Activities
3Media Coverage
1-
American Association for the Advancement of Science (AAAS), EurekAlert!, https://www.eurekalert.org/news-releases/1053401, Aug, 2024 InternetPress release introducing the peer-reviewed paper (doi: 10.1111/cas.16214) https://www.eurekalert.org/news-releases/1053401 Reference source: Fujita Health University (https://www.fujita-hu.ac.jp/en/news/kka9ar0000002gqe.html )
Other
1-
miRNAの発現レベルを利用した婦人科がんの診断技術(関連知財あり、日本特許出願済)) 本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで。